Gyre Therapeutics price to sales ratio GYRE

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 5.5×
6-year median: 7.1×
Against its 6-year history: 27th; percentile: 0 is its lowest day, 100 its highest
6-year range: 1.7× to 29.4×
Peer median: 1.5×

Gyre Therapeutics' price to sales ratio is 5.5× as of Oct 23, 2026.

That is below its 6-year median of 7.1×, lower than on 73% of days in the last 6 years.

Over that time it ranged from 1.7× in May 2022 to 29.4× in Sep 2021.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

median 7.1×

The dashed line is the 6-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.5×	4.8×	7.4×
2025	6.5×	6.1×	10.8×
2024	11.1×	8.6×	11.7×
2023	16.2×	1.9×	20.4×
2022	5.2×	1.7×	11.3×
2021	4.1×	4.1×	29.4×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	113×	113×	157×
2015	169×	89.2×	190×
2014	38.6×	33.4×	47.3×
2013	33.7×	1.9×	46.9×
2012	2.0×	1.4×	2.1×

Against its peers

Companies in Drug Manufacturers - General nearest Gyre Therapeutics' size, closest first, today.

Company	Price to sales ratio
GYREGyre Therapeutics	5.5×
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	4.3×
IRWDIronwood Pharmaceuticals	1.5×
COLLCollegium Pharmaceutical	0.9×
PBYIPuma Biotechnology	2.5×
ABUSArbutus Biopharma	4.6×
ARVNArvinas	1.5×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
PCRXPacira BioSciences	1.9×
Peer median	1.5×

Where Gyre Therapeutics ranks

#85of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Gyre Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.